financetom
Business
financetom
/
Business
/
Ultralife Corporation Files Form 12b-25 Notification of Late Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ultralife Corporation Files Form 12b-25 Notification of Late Filing
Nov 7, 2025 1:56 PM

NEWARK, N.Y., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation ( ULBI ) today announced that it has filed a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission in connection with its Form 10-Q for the third quarter ended September 30, 2025.

As previously disclosed, on October 31, 2024, Ultralife ( ULBI ) completed its acquisition of all outstanding shares of Electrochem Solutions, Inc. (“Electrochem”) from Integer Holdings Corporation (“Integer”). During the third quarter of 2025, the transition services agreement between Ultralife ( ULBI ) and Integer under which Integer maintained the books and records of Electrochem on its information systems concluded, and Electrochem transitioned to Ultralife’s systems. In connection with this transition, Ultralife ( ULBI ) requires additional time to finalize its third quarter results and to provide sufficient time for completion of the review of our third quarter results by our independent accountants without unreasonable effort or expense. Ultralife ( ULBI ) expects to file its Form 10-Q with the Securities and Exchange Commission by November 17, 2025, in accordance with Rule 12b-25.

About Ultralife Corporation ( ULBI )

Ultralife Corporation ( ULBI ) serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife ( ULBI ) serves government, defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include: Battery & Energy Products and Communications Systems. Ultralife ( ULBI ) has operations in North America, Europe and Asia. For more information, visit http://www.ultralifecorporation.com.

Company Contact: Investor Relations Contact:
Ultralife Corporation ( ULBI ) Alliance Advisors IR
Philip A. Fain Jody Burfening/Alex Villalta
(315) 210-6110 (212) 838-3777
[email protected] [email protected]
  [email protected]
Image: https://www.globenewswire.com/newsroom/ti?nf=OTU3MTYwMSM3MjQ5ODM5IzIwMDU2NTA=

Image: https://ml.globenewswire.com/media/NTUwNmY3NzctMTNhMC00YzJhLTg4NDctYTE5NDkxMWEyNzkyLTEwMTcyMjMtMjAyNS0xMS0wNy1lbg==/tiny/Ultralife-Corporation.png Image: Primary Logo

Source: Ultralife Corporation ( ULBI )

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Osisko Metals Edging Up As Announces 100,000-Metre Drilling Campaign at Gaspe Project
Osisko Metals Edging Up As Announces 100,000-Metre Drilling Campaign at Gaspe Project
Feb 10, 2025
10:58 AM EST, 02/10/2025 (MT Newswires) -- Osisko Metals ( OMZNF ) was edging up at last look on Monday after saying the 2025 drill program is underway at its Gaspe Copper project, in eastern Quebec. The 110,000-metres drill program is designed to convert existing inferred resources into indicated or measured resource categories and validate new geological models. A further...
TC BioPharm Completes Initial Group B Dosing in Trial of TCB008 to Treat Acute Myeloid Leukemia
TC BioPharm Completes Initial Group B Dosing in Trial of TCB008 to Treat Acute Myeloid Leukemia
Feb 10, 2025
10:55 AM EST, 02/10/2025 (MT Newswires) -- TC BioPharm ( TCBP ) said Monday it completed dosing for the first group B patient in the Achieve Phase 2B UK trial assessing TCB008 in acute myeloid leukemia. The first group B patient received the dose in October, the company said, adding the person has received all four planned doses of TCB008...
Update: Market Chatter: Springworks Therapeutics in Advanced Talks to be Acquired by Merck KGaA
Update: Market Chatter: Springworks Therapeutics in Advanced Talks to be Acquired by Merck KGaA
Feb 10, 2025
10:55 AM EST, 02/10/2025 (MT Newswires) -- (Updates with Springworks response in the final paragraph.) Spingworks Therapeutics (SWTX) is in advanced talks to be acquired by Merck KGaA, Reuters reported Monday, citing unnamed people familiar with the matter. According to the report, a deal could be signed in the coming weeks if the talks are successful. Springworks declined to comment...
Rockwell Automation Maintains 2025 Earnings Outlook Amid Fiscal First-Quarter Bottom-Line Beat
Rockwell Automation Maintains 2025 Earnings Outlook Amid Fiscal First-Quarter Bottom-Line Beat
Feb 10, 2025
10:58 AM EST, 02/10/2025 (MT Newswires) -- Rockwell Automation ( ROK ) affirmed its full-year earnings outlook on Monday as the industrial automation company's bottom-line results for the fiscal first quarter came in ahead of Wall Street estimates. Adjusted earnings came in at $1.83 a share for the quarter ended Dec. 31, down from $2.04 the year before, but above...
Copyright 2023-2026 - www.financetom.com All Rights Reserved